MicroRNA panel provides a more precise lung cancer diagnosis

Sep 29, 2010

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

Tina B. Edmonston, M.D., director of the clinical laboratory at Rosetta Genomics, Inc., presented data on the assay at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, held here.

Lung cancers are traditionally divided into two main groups, either neuroendocrine or non-small cell . In 20 to 30 percent of the cases it is difficult to make a definitive diagnosis of the tumor subtype using fine needle biopsy.

"Subclassification has become very important in the determination of patient management," said Edmonston. "This subclassification leads to treatment decisions, so it is very important to make the accurately."

Using their proprietary assay, which is still under development, Edmonston and colleagues were able to further subclassify non-small cell lung cancer into squamous and non-squamous, and neuroendocrine into small cell lung cancer and carcinoid with a high level of sensitivity and specificity.

Edmonston said this assay would result in better treatment decisions because not all subtypes of lung cancer will respond to certain drugs and some may even pose unique risks.

Explore further: Discovery could lead to new cancer treatment

add to favorites email to friend print save as pdf

Related Stories

New genetic techniques to combat lung cancer

Apr 25, 2008

New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) ...

Recommended for you

Discovery could lead to new cancer treatment

Aug 29, 2014

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

Is the HPV vaccine necessary?

Aug 29, 2014

As the school year starts in full swing many parents wonder if their child should receive the HPV vaccine, which is recommended for girls ages 11-26 and boys 11-21. There are a lot of questions and controversy around this ...

User comments : 0